Brain Fag Syndrome and Stimulant Use Among Undergraduate

Total Page:16

File Type:pdf, Size:1020Kb

Brain Fag Syndrome and Stimulant Use Among Undergraduate BRAIN FAG SYNDROME AND STIMULANT USE AMONG UNDERGRADUATE STUDENTS AT THE UNIVERSITY OF BENIN A DISSERTATION SUBMITTED TO THE NATIONAL POSTGRADUATE MEDICAL COLLEGE OF NIGERIA IN PART FULFILLMENT OF THE REQUIREMENTS FOR THE FELLOWSHIP OF THE COLLEGE IN THE FACULTY OF PSYCHIATRY FMC PSYCH. (NIG). BY Dr. Ehigiator Okokhue Adayonfo M.B.B.S (UNIVERSITY OF BENIN) 2000. DEPARTMENT OF MENTAL HEALTH UNIVERSITY OF BENIN TEACHING HOSPITAL BENIN CITY, EDO STATE NIGERIA. NOVEMBER 2012 i ii DEDICATION This study is dedicated to the Almighty God. iii ACKNOWLEDGEMENT I express profound gratitude to Prof. O. Morakinyo, Dr. K. O. Akhigbe (My Supervisor and 2nd Supervisor respectively), Dr. E. Uwadiae (My Head of Department, Department of Mental Health, University of Benin Teaching Hospital, Benin City), Dr. S.O. Osasona (Postgraduate Training Co-ordinator, Department of Mental Health, University of Benin Teaching Hospital, Benin City) and Mr. O. Onofigho. My thanks also go to Dr. V. Asemota and Dr. I. Aina, all resident doctors and indeed all staff of the Department of Mental Health, University of Benin Teaching Hospital, and all authors whose work were cited in this study. I am also grateful to Dr. B.O. James, Mr. G.N. Okungbowa and Mr. I. Enang; the authorities of the University of Benin and the undergraduate students used for this study cooperated immensely, for which I am grateful. I am also very grateful to my wife, children, parents and siblings for their support and understanding. Finally, to God be the glory! iv SUMMARY Brain Fag Syndrome (BFS) which was first described by Raymond Prince in Nigeria in 1960, has continued to be studied. It is a culture bound syndrome found in Africans who are engaged in intellectual activities. It constitutes an impediment to the goal of studentship as it may lead to student wastage and or school dropout. Some theories have been put forward to explain the aetiology of BFS. Prince put forward the Forbidden Knowledge and the Ego Energy theories while Morakinyo Olufemi propounded the Psychophysiological or Circular Theory which links BFS to stimulant use. Most appealing is the Psychophysiological Theory, which could be subjected to empirical study. However, there is a dearth of study to link BFS to stimulant use. The aims of this cross-sectional study were; to determine the prevalence of BFS and stimulant use among undergraduate students at the University of Benin, determine any association between the two, to know the socio-demographic factors associated with BFS and to identify factors that may contribute to BFS among students who use stimulants. Multistage sampling technique was used to select five hundred, 300-level students from 7 of the 13 Faculties in the University, but 482 questionnaires were analysed due to attrition. Prevalence of BFS and past 30 days general stimulant use among the respondents were high (42.9% and 39.4% respectively). There was a statistically significant association between BFS and use of stimulants by the respondents. The study supported the Psychophysiological theory because BFS was common among the respondents that used stimulants. There was no significant difference between the socio-demographic characteristics of students who had BFS and those who did not. The study showed a significant positive v correlation between general psychiatric morbidity and BFS, in that BFS was significantly common among the respondents who were GHQ positive. Gender and general psychiatric morbidity were significantly associated with the respondents who used stimulants and came down with BFS. BFS was commoner among females than males who used stimulants, and among the students who used stimulants that were positive on the GHQ. Consequent upon the earlier mentioned findings, Nigerian undergraduate students may mind the use of stimulants during studies to forestall their coming down with BFS. Undergraduate students in Nigeria may learn the right study habits that would not need the use of stimulants to stay awake. In addition, mental health service provision as a part of the University health services rendered to the University community, for early detection and treatment of such problems as BFS among the undergraduate students. This could minimize BFS and the rate of dropout among the students, for the good of the Nigerian society. vi CONTENTS Declaration --------------------------------------------------------------------------------- i Certification--------------------------------------------------------------------------------- ii Dedication----------------------------------------------------------------------------------- iii Acknowledgement------------------------------------------------------------------------- iv Summary------------------------------------------------------------------------------------ v Table of Contents-------------------------------------------------------------------------- vii Introduction and Relevance of the study----------------------------------------------- 1 Literature Review------------------------------------------------------------------------- 5 Aims, Objectives and Hypothesis------------------------------------------------------- 21 Methodology------------------------------------------------------------------------------- 23 Results-------------------------------------------------------------------------------------- 34 Discussion---------------------------------------------------------------------------------- 65 Conclusion--------------------------------------------------------------------------------- 75 Limitations of the study------------------------------------------------------------------ 76 Recommendations------------------------------------------------------------------------ 77 References--------------------------------------------------------------------------------- 78 Appendices-------------------------------------------------------------------------------- 89 vii Chapter One INTRODUCTION Prince classified Brain Fag Syndrome (BFS) as a culture-bound syndrome (Prince, 1985; DSM-IV, 1994; Aina and Morakinyo, 2011). It was first described by him in Nigeria in 1960 (Prince, 1960), and it occurs commonly among African people involved in intellectual activities, such as students. Prince (1962) described the features of the syndrome as: (1) Intellectual impairment manifesting as inability to grasp the meaning of materials read, poor retention and recall, and difficulty with concentrating while reading. (2) Unpleasant sensations like heat or burning , pains, aches, and peppery feeling around the head and neck that are associated with study; either coming on when a student attempts academic activity or may be continuously present but becoming exacerbated when studying. Other sensory disturbances include blurring of vision or just seeing blank. (3) Fatigue and sleepiness in spite of adequate rest. (4) Affective disturbances may or may not be present, or volunteered by the student but may take the form of fear, anxiety and/or depression if present. Prince called the syndrome, “Brain fag” (BFS) since this was the phrase used by the students to describe the illness, which they believed was the result of brain fatigue. BFS was observed among students in other parts of Africa or in students of African origin studying abroad. On the contrary, the syndrome is rare among Caucasians (German, Assael, Muhangi, 1970; Wintrob, 1971; Lehmann, 1972; Thebaud and Rigamer, 1976; Minde, 1974). There are contentions about BFS been a separate nosological entity. Various researchers classified it as a depressive disorder, somatisation disorder, and an anxiety disorder or an anxiety depressive equivalent. Neki and Marinho (1968), and Guinness (1992b) classified 1 BFS as either a depressive disorder or an anxiety state; Jegede (1983), and Anumonye (1983); Peltzer, Cherian and Cherian (1988) opined that it was an anxiety-depression equivalent; while Mbanefo (1966), Ayorinde (1977), Ebigbo and Ihezue (1981), Nwezie (1982) and Ezeilo (1982) classified BFS as a somatisation disorder. Fatoye and Morakinyo (2003), regard BFS as a distinct syndrome which incorporates features of somatisation, obsession and depressive disorders. Ola, Morakinyo and Adewuya claimed that BFS was real and not a myth (Ola, Morakinyo and Adewuya, 2009). “The confusion about the nosological status of BFS seems to result from speculative opinions, failure to define the syndrome properly by authors, lack of biological markers to complement the clinical phenotype of the condition and the fact that most studies did not use the brain fag syndrome scale which is based on the definition of the syndrome” (Ola, Morakinyo and Adewuya, 2009). Nevertheless, the components of the syndrome draw a line of demarcation between it and other related ones, hence the reason for BFS as a distinct diagnostic entity. In addition, this could be one of the reasons the International Classification of Diseases (ICD-10) grouped it under “Neurotic, Stress Related and Somatoform Disorder, F48.8 (WHO, 1992), while the Diagnostic and Statistical Manual (DSM-IV) regards it as a Culture-Bound Syndrome (“Appendix I; Outline for Cultural Formulation and Glossary of Culture-Bound Syndromes”) (DSM-IV, 1994)). A few reports may indicate that Brain fag syndrome is common. Prince reported an average prevalence of 54 % among secondary school students in Ibadan, Nigeria (Prince, 1962). Peltzer, Cherian and Cherian reported a prevalence of 25% among secondary school students in South Africa (Peltzer, Cherian and Cherian, 1998), Fatoye reported
Recommended publications
  • IOC Doping Control Guide For
    Doping Control Guide Version 1.0 | February 2016 CONTENTS 1 | ! GENERAL INFORMATION ...................................................... 2! 2 | ! DOPING CONTROL ............................................................. 2! 3 | ! DOPING CONTROL STEP-BY-STEP ........................................... 3! 4 | ! LABORATORY ................................................................... 4! 5 | ! MEDICATIONS USE ............................................................. 4! 6 | ! SUPPLEMENT USE .............................................................. 4! 7 | ! THERAPEUTIC USE EXEMPTIONS ............................................. 5! 8 | ! WHEREABOUTS INFORMATION ............................................... 5! 9 | ! RESOLVING PENDING CASES INVOLVING POSSIBLE VIOLATIONS OF ANTI-DOPING RULES .......................................................... 6! 10 |!WADA INDEPENDENT OBSERVER PROGRAMME ............................. 6! 11 |!WADA OUTREACH PROGRAMME ............................................ 7! 12 |!SHARE OF INFORMATION THROUGH SECURE DATABASE ................. 7! 13 |!DOPING CONTROL TECHNICAL PROCEDURES FOR RIO 2016 OLYMPIC GAMES ............................................................... 7! APPENDICES .......................................................................... 8! A1| DOPING CONTROL STEP-BY-STEP POSTER .................................. 8! A2|THE 2016 PROHIBITED LIST .................................................... 9! SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) .........................................................
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST
    UFC PROHIBITED LIST Effective June 1, 2021 THE UFC PROHIBITED LIST UFC PROHIBITED LIST Effective June 1, 2021 PART 1. Except as provided otherwise in PART 2 below, the UFC Prohibited List shall incorporate the most current Prohibited List published by WADA, as well as any WADA Technical Documents establishing decision limits or reporting levels, and, unless otherwise modified by the UFC Prohibited List or the UFC Anti-Doping Policy, Prohibited Substances, Prohibited Methods, Specified or Non-Specified Substances and Specified or Non-Specified Methods shall be as identified as such on the WADA Prohibited List or WADA Technical Documents. PART 2. Notwithstanding the WADA Prohibited List and any otherwise applicable WADA Technical Documents, the following modifications shall be in full force and effect: 1. Decision Concentration Levels. Adverse Analytical Findings reported at a concentration below the following Decision Concentration Levels shall be managed by USADA as Atypical Findings. • Cannabinoids: natural or synthetic delta-9-tetrahydrocannabinol (THC) or Cannabimimetics (e.g., “Spice,” JWH-018, JWH-073, HU-210): any level • Clomiphene: 0.1 ng/mL1 • Dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3): 0.1 ng/mL • Selective Androgen Receptor Modulators (SARMs): 0.1 ng/mL2 • GW-1516 (GW-501516) metabolites: 0.1 ng/mL • Epitrenbolone (Trenbolone metabolite): 0.2 ng/mL 2. SARMs/GW-1516: Adverse Analytical Findings reported at a concentration at or above the applicable Decision Concentration Level but under 1 ng/mL shall be managed by USADA as Specified Substances. 3. Higenamine: Higenamine shall be a Prohibited Substance under the UFC Anti-Doping Policy only In-Competition (and not Out-of- Competition).
    [Show full text]
  • MRO Manual Before 2004
    Note: This manual is essentially the same as the 1997 HHS Medical Review Officer (MRO) Manual except for changes related to the new Federal Custody and Control Form (CCF). The appendix has also been deleted since the new Federal Custody and Control Form is available as a separate file on the website. Medical Review Officer Manual for Federal Agency Workplace Drug Testing Programs for use with the new Federal Drug Testing Custody and Control Form (OMB Number 0930-0158, Exp Date: June 30, 2003) This manual applies to federal agency drug testing programs that come under Executive Order 12564 and the Department of Health and Human Services (HHS) Mandatory Guidelines. Table of Contents Chapter 1. The Medical Review Officer (MRO) ............................................................... 1 Chapter 2. Federal Drug Testing Custody and Control Form .......................................... 3 Chapter 3. The MRO Review Process ............................................................................ 3 A. Administrative Review of the CCF ........................................................................... 3 I. State Initiatives and Laws ....................................................................................... 15 Chapter 4. Specific Drug Class Issues .......................................................................... 15 A. Amphetamines ....................................................................................................... 15 B. Cocaine ................................................................................................................
    [Show full text]
  • Enantiomeric Profiling of Chiral Illicit Drugs in a Pan-European Study Erika Castrignanòa**, Zhugen Yanga,B, Richard Badec,D, J
    This document is the accepted manuscript version of the following article: Castrignanò, E., Yang, Z., Bade, R., Baz-Lomba, J. A., Castiglioni, S., Causanilles, A., … Kasprzyk-Hordern, B. (2018). Enantiomeric profiling of chiral illicit drugs in a pan-European study. Water Research, 130, 151-160. https:// doi.org/10.1016/j.watres.2017.11.051 This manuscript version is made available under the CC-BY-NC-ND 4.0 license http:// creativecommons.org/licenses/by-nc-nd/4.0/ Enantiomeric profiling of chiral illicit drugs in a pan-European study Erika Castrignanòa**, Zhugen Yanga,b, Richard Badec,d, Jose A. Baz-Lombae, Sara Castiglionif, Ana Causanillesg, Adrian Covacih, Emma Gracia-Lorc,f, Felix Hernandezc, Juliet Kinyuah, Ann- Kathrin McCalli, Alexander L. N. van Nuijsh, Christoph Orti, Benedek G. Plószj,k, Pedram Raminj,l, Nikolaos I. Rousisf, Yeonsuk Ryue, Kevin V. Thomase,m, Pim de Voogtg,n, Ettore Zuccatof and Barbara Kasprzyk-Horderna* a Department of Chemistry, Faculty of Science, University of Bath, Bath, BA2 7AY, United Kingdom (UK) b Division of Biomedical Engineering, School of Engineering, University of Glasgow, Oakfield Road, Glasgow G12 8LT, UK c Research Institute for Pesticides and Water, University Jaume I, Avda. Sos Baynat s/n, E-12071, Castellón, Spain d School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia 5000, Australia e Norwegian Institute for Water Research (NIVA), Gaustadalleen 21, 0349, Oslo, Norway f IRCCS Istituto di Ricerche Farmacologiche “Mario Negri”, Department of Environmental Health Sciences, Via La Masa 19, 20156, Milan, Italy g KWR Watercycle Research Institute, Chemical Water Quality and Health, P.O.
    [Show full text]
  • Predictable Increase of Central Nervous System Stimulation by a Pyrolysis Product in Smoking Dimethylamphetamine
    264 Journal of Health Science, 50(3) 264–270 (2004) Predictable Increase of Central Nervous System Stimulation by a Pyrolysis Product in Smoking Dimethylamphetamine Motoyasu Sato,*, a Kenjiro Ito,a and Hisamitsu Nagaseb aScientific Investigation Research Laboratory, Aichi Pref. Police H.Q., 2–1–1 Sannomaru, Naka-ku, Nagoya 460–8502, Japan and bGifu Pharmaceutical University, 5–6–1 Mitahora-higashi, Gifu 502–8585, Japan (Received January 10, 2004; Accepted February 6, 2004) We carried out a dimethylamphetamine (DMA) smoking experiment that is closer to some real cases. In this study, we heated DMA hydrochloride (DMA-HCl) in the range of about 250°C to 350°C, in which demethylation reaction occurred mainly, with a smoke collection apparatus and gas lighter, and trapped the generating vapor with an adsorption cartridge. The eluate desorbed from the cartridge and residual materials inside the smoke collection apparatus were analyzed by gas chromatography-mass spectrometry and liquid chromatography-electrospray ion- ization-mass spectrometry. Methamphetamine (MA) and amphetamine (AM) were produced via demethylation from the dimethylamino group of DMA. Allylbenzene (AB), benzaldehyde (BA), cis-β-methylstyrene (cMS), benzyl chloride (BC) and trans-β-methylstyrene (tMS) in addition to MA and AM, were also formed as pyrolysis products. The molar percentages of a pyrolyzate MA and AM to the starting DMA were 21.4 and 1.8%, respectively, and the total molar percentage of AB, BA, cMS, BC and tMS was 2.9%. Taking into account the central nervous system stimulation by DMA and MA in humans, the total stimulant effects of the drugs that are ingested in a body can be calculatedly increased more than fourfold by smoking DMA.
    [Show full text]
  • 2008 Prohibited List
    The World Anti-Doping Code THE 2008 PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2008 The Prohibited List 2008 September 22, 2007 THE 2008 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 2008 The use of any drug should be limited to medically justified indications SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstendiol (5α-androst-1-ene-3β,17β-diol ); 1-androstendione (5α- androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta- 1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en- 17β-ol); drostanolone; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17β-hydroxy-17α-methyl-5α- androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β- dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); methandriol; methasterone (2α, 17α-dimethyl-5α-androstane-3-one-17β-ol);
    [Show full text]
  • Analytical Reference Standards
    Cerilliant Quality ISO GUIDE 34 ISO/IEC 17025 ISO 90 01:2 00 8 GM P/ GL P Analytical Reference Standards 2 011 Analytical Reference Standards 20 811 PALOMA DRIVE, SUITE A, ROUND ROCK, TEXAS 78665, USA 11 PHONE 800/848-7837 | 512/238-9974 | FAX 800/654-1458 | 512/238-9129 | www.cerilliant.com company overview about cerilliant Cerilliant is an ISO Guide 34 and ISO 17025 accredited company dedicated to producing and providing high quality Certified Reference Standards and Certified Spiking SolutionsTM. We serve a diverse group of customers including private and public laboratories, research institutes, instrument manufacturers and pharmaceutical concerns – organizations that require materials of the highest quality, whether they’re conducing clinical or forensic testing, environmental analysis, pharmaceutical research, or developing new testing equipment. But we do more than just conduct science on their behalf. We make science smarter. Our team of experts includes numerous PhDs and advance-degreed specialists in science, manufacturing, and quality control, all of whom have a passion for the work they do, thrive in our collaborative atmosphere which values innovative thinking, and approach each day committed to delivering products and service second to none. At Cerilliant, we believe good chemistry is more than just a process in the lab. It’s also about creating partnerships that anticipate the needs of our clients and provide the catalyst for their success. to place an order or for customer service WEBSITE: www.cerilliant.com E-MAIL: [email protected] PHONE (8 A.M.–5 P.M. CT): 800/848-7837 | 512/238-9974 FAX: 800/654-1458 | 512/238-9129 ADDRESS: 811 PALOMA DRIVE, SUITE A ROUND ROCK, TEXAS 78665, USA © 2010 Cerilliant Corporation.
    [Show full text]
  • 2013 Prohibited List
    The World Anti-Doping Code THE 2013 PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2013- The 2013 Prohibited List 10 September 2012 THE 2013 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 2013 In accordance with Article 4.2.2 of the World Anti-Doping Code, all Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S4.4, S4.5, S6.a, and Prohibited Methods M1, M2 and M3. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S0. NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstenediol (5α-androst-1-ene-3β,17β-diol ); 1-androstenedione (5α- androst-1-ene-3,17-dione); bolandiol (estr-4-ene-3β,17β-diol ); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol);
    [Show full text]
  • Pharmacology of Stimulants Prohibited by the World Anti-Doping Agency (WADA)
    British Journal of Pharmacology (2008) 154, 606–622 & 2008 Nature Publishing Group All rights reserved 0007– 1188/08 $30.00 www.brjpharmacol.org REVIEW Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA) JR Docherty Department of Physiology, Royal College of Surgeons in Ireland, Dublin, Ireland This review examines the pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA). Stimulants that increase alertness/reduce fatigue or activate the cardiovascular system can include drugs like ephedrine available in many over- the-counter medicines. Others such as amphetamines, cocaine and hallucinogenic drugs, available on prescription or illegally, can modify mood. A total of 62 stimulants (61 chemical entities) are listed in the WADA List, prohibited in competition. Athletes may have stimulants in their body for one of three main reasons: inadvertent consumption in a propriety medicine; deliberate consumption for misuse as a recreational drug and deliberate consumption to enhance performance. The majority of stimulants on the list act on the monoaminergic systems: adrenergic (sympathetic, transmitter noradrenaline), dopaminergic (transmitter dopamine) and serotonergic (transmitter serotonin, 5-HT). Sympathomimetic describes agents, which mimic sympathetic responses, and dopaminomimetic and serotoninomimetic can be used to describe actions on the dopamine and serotonin systems. However, many agents act to mimic more than one of these monoamines, so that a collective term of monoaminomimetic may be useful. Monoaminomimietic actions of stimulants can include blockade of re-uptake of neurotransmitter, indirect release of neurotransmitter, direct activation of monoaminergic receptors. Many of the stimulants are amphetamines or amphetamine derivatives, including agents with abuse potential as recreational drugs.
    [Show full text]
  • Forensic Chemistry of Substance Misuse a Guide to Drug Control
    Forensic Chemistry of Substance Misuse A Guide to Drug Control Forensic Chemistry of Substance Misuse A Guide to Drug Control L. A. King ISBN: 978-0-85404-178-7 A catalogue record for this book is available from the British Library r L. A. King 2009 All rights reserved Apart from fair dealing for the purposes of research for non-commercial purposes or for private study, criticism or review, as permitted under the Copyright, Designs and Patents Act 1988 and the Copyright and Related Rights Regulations 2003, this publication may not be reproduced, stored or transmitted, in any form or by any means, without the prior permission in writing of The Royal Society of Chemistry or the copyright owner, or in the case of reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK, or in accordance with the terms of the licences issued by the appropriate Reproduction Rights Organization outside the UK. Enquiries concerning reproduction outside the terms stated here should be sent to The Royal Society of Chemistry at the address printed on this page. Published by The Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge CB4 0WF, UK Registered Charity Number 207890 For further information see our web site at www.rsc.org Preface ‘‘Gold is worse poison to a man’s soul, doing more murders in this loathsome world, than any mortal drug’’ William Shakespeare (Romeo and Juliet) An earlier publication1 described the UK drugs legislation from the viewpoint of a forensic scientist. In the current book, an opportunity has been taken to rearrange and expand the material and improve clarity, to include the changes that have occurred in the past six years, and, more importantly, to widen the scope and the intended audience.
    [Show full text]
  • Anti-Doping Convention
    European Treaty Series - No. 135 Anti-Doping Convention Strasbourg, 16.XI.1989 Appendix – AMENDMENTS TO THE APPENDIX (approved by the Monitoring Group under Article 11.1.b of the Convention at its 51st meeting) (Strasbourg, 24 October 2019) THE 2020 PROHIBITED LIST - WORLD ANTI-DOPING CODE DATE OF ENTRY INTO FORCE: 1 JANUARY 2020 SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S.4.4, S.4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES 1-Testosterone (17β-hydroxy-5α-androst-1- en-3-one); S0. NON-APPROVED SUBSTANCES 4-Androstenediol (androst-4-ene-3β,17β-diol); 4-Hydroxytestosterone (4,17β- Any pharmacological substance which is not dihydroxyandrost-4-en-3one); addressed by any of the subsequent sections of 5-Androstenedione (androst-5-ene-3,17- the List and with no current approval by any dione); governmental regulatory health authority for 7α-hydroxy-DHEA; human therapeutic use (e.g. drugs under pre- 7β-hydroxy-DHEA; clinical or clinical development or discontinued, 7-Keto-DHEA; designer drugs, substances approved only for 19-Norandrostenediol (estr-4-ene-3,17-diol); veterinary use) is prohibited at all times. 19-Norandrostenedione (estr-4-ene-3,17- dione); S1. ANABOLIC AGENTS Androstanolone (5α-dihydrotestosterone, 17β- hydroxy-5αandrostan-3-one); Anabolic agents are prohibited. Androstenediol (androst-5-ene-3β,17β-diol);
    [Show full text]